Egalet (EGLT) Stock Price, News & Analysis

Company Overview

Egalet Corporation, a specialty pharmaceutical company, develops, manufactures, and commercializes treatments for patients with pain and other conditions. It has licensed three approved pain products, such as SPRIX Nasal Spray, a non-steroidal anti-inflammatory drug indicated in adult patients for the short-term management of moderate to moderately severe pain that requires analgesia at the opioid level; OXAYDO, an immediate-release oxycodone product designed to discourage abuse via snorting for the management of acute and chronic pain severe enough to require an opioid analgesic, and for which alternative treatments are inadequate; and ARYMO ER, an extended-release (ER) morphine product formulated with abuse-deterrent (AD) properties for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. The company is also developing Egalet-002, a Guardian Technology AD, ER, oral oxycodone formulation, which is in Phase III clinical trials for the same indication as ARYMO ER. In addition, its other products include Egalet-003, an AD stimulant product candidate; and Egalet-004, an AD, ER hydrocodone-based product candidate. The company has a collaboration and license agreement with Acura Pharmaceuticals, Inc. to commercialize OXAYDO tablets; and Septodont, Inc. to promote SPRIX Nasal Spray. Egalet Corporation was founded in 2010 and is headquartered in Wayne, Pennsylvania.

Key Stats

• Today's Range: $0.0080 to $0.0080
• 50-Day Range: $0.01 to $0.33
• 52-Week Range: $0.03 to $1.57
• Volume: N/A
• Average Volume: 853,425 shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

EGLT Stock Analysis - Frequently Asked Questions

How were Egalet's earnings last quarter?

Egalet (NASDAQ:EGLT) released its quarterly earnings data on Wednesday, August, 8th. The specialty pharmaceutical company reported ($0.22) earnings per share for the quarter, topping analysts' consensus estimates of ($0.28) by $0.06. The specialty pharmaceutical company had revenue of $7.44 million for the quarter, compared to analyst estimates of $8.64 million.

What other stocks do shareholders of Egalet own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Egalet investors own include Novavax (NVAX), Palo Alto Networks (PANW), Cara Therapeutics (CARA), TG Therapeutics (TGTX), Ocular Therapeutix (OCUL), Trevena (TRVN) and 22nd Century Group (XXII).

Company Calendar

• Last Earnings: 8/08/2018
• Today: 11/14/2024

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical Preparations
• Sub-Industry: N/A
• Current Symbol: NASDAQ:EGLT
• CUSIP: N/A
• CIK: 1586105
• Web: www.egalet.com
• Phone: 610-833-4200
• Fax: N/A
• Employees: N/A
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Optionable
• Beta: N/A